{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:54:00Z","timestamp":1763445240706,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/bmt.2017.63","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T14:21:30Z","timestamp":1491229290000},"page":"1003-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Predictors of overall survival among patients treated with sirolimus\/tacrolimus vs methotrexate\/tacrolimus for GvHD prevention"],"prefix":"10.1038","volume":"52","author":[{"given":"F","family":"Khimani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7643-2422","authenticated-orcid":false,"given":"B","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"T","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Nieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Anasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"BFbmt201763_CR1","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.bbmt.2010.05.019","volume":"16","author":"JE Levine","year":"2010","unstructured":"Levine JE, Logan B, Wu J, Alousi AM, Ho V, Bola\u00f1os-Meade J et al. Graft-versus-host disease treatment: predictors of survival. Biol Blood Marrow Transplant 2010; 16: 1693\u20131699.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR2","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.bbmt.2010.01.007","volume":"16","author":"J Pidala","year":"2010","unstructured":"Pidala J, Anasetti C . Glucocorticoid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 1504\u20131518.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR3","first-page":"2062","volume":"96","author":"RA Nash","year":"2000","unstructured":"Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062\u20132068.","journal-title":"Blood"},{"key":"BFbmt201763_CR4","first-page":"2303","volume":"92","author":"V Ratanatharathorn","year":"1998","unstructured":"Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303\u20132314.","journal-title":"Blood"},{"key":"BFbmt201763_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbmt.2005.02.006","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383\u2013388.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR6","doi-asserted-by":"crossref","unstructured":"Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B et al. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2014; (7): CD010280.","DOI":"10.1002\/14651858.CD010280.pub2"},{"key":"BFbmt201763_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2014.57.2446","volume":"33","author":"M Eapen","year":"2015","unstructured":"Eapen M, Logan BR, Horowitz MM, Zhong X, Perales M-A, Lee SJ et al. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol 2015; 33: 364\u2013369.","journal-title":"J Clin Oncol"},{"key":"BFbmt201763_CR8","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2006-09-046219","volume":"109","author":"C Cutler","year":"2007","unstructured":"Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108\u20133114.","journal-title":"Blood"},{"key":"BFbmt201763_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.bbmt.2008.02.009","volume":"14","author":"T Furlong","year":"2008","unstructured":"Furlong T, Kiem H-P, Appelbaum FR, Carpenter PA, Deeg HJ, Doney K et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008; 14: 531\u2013537.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood-2009-03-207563","volume":"115","author":"R Rodriguez","year":"2010","unstructured":"Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A et al. A phase II pilot study of tacrolimus\/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115: 1098\u20131105.","journal-title":"Blood"},{"key":"BFbmt201763_CR11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","volume":"97","author":"J Pidala","year":"2012","unstructured":"Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 2012; 97: 1882\u20131889.","journal-title":"Haematologica"},{"key":"BFbmt201763_CR12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","volume":"124","author":"C Cutler","year":"2014","unstructured":"Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D et al. Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014; 124: 1372\u20131377.","journal-title":"Blood"},{"key":"BFbmt201763_CR13","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFbmt201763_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","volume":"18","author":"JB Perkins","year":"2012","unstructured":"Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1099\u20131107.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945\u2013956.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR16","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201763_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED . Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116\u2013122.","journal-title":"Hepatology"},{"key":"BFbmt201763_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","volume":"11","author":"VT Ho","year":"2005","unstructured":"Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571\u2013575.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17: 204.","journal-title":"Crit Care"},{"key":"BFbmt201763_CR20","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015; 125: 1333\u20131338.","journal-title":"Blood"},{"key":"BFbmt201763_CR21","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"R Gray","year":"1988","unstructured":"Gray R . A class of K-sample tests for comparing the cumulative incidence of competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFbmt201763_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"J Fine","year":"1999","unstructured":"Fine J, Gray R . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt201763_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.13931","volume":"173","author":"P Armand","year":"2016","unstructured":"Armand P, Kim HT, Sainvil M-M, Lange PB, Giardino AA, Bachanova V et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 2016; 173: 96\u2013104.","journal-title":"Br J Haematol"},{"key":"BFbmt201763_CR24","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3324\/haematol.2016.149294","volume":"101","author":"J T\u00f6rl\u00e9n","year":"2016","unstructured":"T\u00f6rl\u00e9n J, Ringd\u00e9n O, Garming-Legert K, Ljungman P, Winiarski J, Remes K et al. A prospective randomized trial comparing cyclosporine\/methotrexate and tacrolimus\/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica 2016; 101: 1417\u20131425.","journal-title":"Haematologica"},{"key":"BFbmt201763_CR25","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bbmt.2003.12.304","volume":"10","author":"PJ Martin","year":"2004","unstructured":"Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004; 10: 320\u2013327.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201763_CR26","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3324\/haematol.2015.123588","volume":"100","author":"J Pidala","year":"2015","unstructured":"Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF et al. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica 2015; 100: 970\u2013977.","journal-title":"Haematologica"},{"key":"BFbmt201763_CR27","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","volume":"112","author":"C Cutler","year":"2008","unstructured":"Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112: 4425\u20134431.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201763","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.63","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T20:04:40Z","timestamp":1648065880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFbmt201763"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.63","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2017,4,3]]},"assertion":[{"value":"23 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}